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Summary. Objective. The objective of this study was to investigate the prevalence of HCV
(hepatitis C virus) infection in hemophilia patients in Latvia and to analyze association between
natural clearance of HCV and human leukocyte antigen (HLA) class II genes.
Material and methods. From 61 hemophilic patients participating in this study, 38 were adults
and 23 were pediatric patients younger than 18 years. To analyze association between HLA class
II alleles and natural clearance of HCV, the gene frequency was compared in hemophilia patients
group and the control group of 60 healthy subjects, all men. Serum HCV RNA was qualitatively
determined and HLA class II alleles were identified by polymerase chain reaction (PCR) method.
Results. HCV infection is common among hemophilia patients in Latvia. Antibodies to HCV
were found in 45 of 61 (74%) hemophilia patients. In 41% of hemophilia patients (18 of 44), HCV
infection resolved spontaneously. Children cleared HCV more frequently than adults (7 of 11
comparing to 11 of 33, respectively; OR=3.50; P<0.05). The frequency difference was found to
be statistically significant when comparing HLA alleles distribution in the sample of hemophilia
patients who naturally cleared HCV (n=18) and in the control group (n=60) (corresponding
frequency of HLA-DRB1*07 allele – 4 (11.11%) and 9 (1.67%); OR=7.38; P<0.05).
Conclusions. Natural clearance of HCV infection is frequently found in hemophilia patients
in Latvia. Children are more likely to clear virus naturally than adults. There is an association
between natural clearance of HCV and HLA allele DRB1*07 in hemophilia patients.
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Introduction
Chronic hepatitis is an important public health
problem affecting more than 500 million people
worldwide (1) and 80–100 thousand in Latvia (2).
According to literature data, hepatitis C virus (HCV)
is the major cause of chronic liver disease in adults
and children with hemophilia (3). Before the intro-
duction of HCV screening of human blood products,
most of children with hemophilia were infected with
HCV. In Latvia screening of donated blood for pres-
ence of anti-HCV was introduced in November 1993.
Cryoprecipitate and fresh-frozen plasma for treatment
of hemophilia patients were used until June 2000.
Approximately 10% (4) to 50% (5, 6) of patients who
were infected with HCV have been shown to clear
the infection naturally. Higher rates of spontaneous
resolution of HCV infection have been observed in
some patient subgroups such as young women after a
common-source outbreak of contaminated anti-D
immunoglobulin, children infected with HCV while
undergoing cardiac surgery or cancer chemotherapy,
or in healthcare workers after a needle stick injury
(7). The mechanisms underlying the spontaneous viral
clearance or development of chronic HCV infection
have not been clearly identified yet (8). Apart from
viral characteristics (viral genotype, quasispecies
distribution, and viral load), it is generally accepted
that cellular immune responses play an important role
in viral clearance and disease resolution (5).
The outcome of HCV infection is determined by
complex host-virus interactions (9) and based on
studies involving hemophilia patients; it seems that
genetic factors have rather modest influence on the
outcome of hepatitis C (7). Nevertheless, immune
system, including human leukocyte antigen (HLA)
complex, plays an important role in natural clearance
of HCV (10) and is worth examining in different pop-
ulations.
Hemophilia patients who received unsterilized
blood products such cryoprecipitate have extremely
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high prevalence of HCV infection reaching 90% in
many countries (7, 11). The preliminary analysis
showed that Latvia is not an exception in terms of
HCV infection prevalence in hemophiliacs. Since
modern treatment options are available now, it was
important to determine the prevalence of HCV infec-
tion among hemophilia patients in Latvia in order to
determine those who need treatment and those who
cleared virus naturally. By analyzing the group of
hemophilia patients who have cleared HCV naturally,
possible reasons of this phenomenon were found and
described. The study of HCV infection in hemophil-
iacs has been performed in Latvia for the first time.
There are also not so many studies of this kind per-
formed in different countries around the world. The
most important study so far, trying to find answers
for reasons of natural clearance of HCV and including
257 sibling pairs from 3993 hemophilic patients, has
been published recently (7). Our study focused more
on one internal factor, namely, some HLA II class
alleles, that could contribute to spontaneous resolution
of HCV infection in population in Latvia. The results
of different studies confirm the negative association
between chronic HCV infection and DQB1*0301 allele
(12). Association of DQB1*0301 allele with natural
clearance of HCV is mentioned by many authors in
original studies and reviews (10, 12–23). The other
allele described as being important in patients who
clear HCV spontaneously is DRB1*1101 (13, 16, 18,
20–24).
The objective of this study was to investigate the
prevalence of HCV infection in hemophilia patients
in Latvia and to analyze the association between
natural clearance of HCV and HLA class II genes.
The another objective was to determine distribu-
tion of HCV genotypes in children and adults with
hemophilia in Latvia.
Material and methods
Subjects. Serum samples were obtained from 61
patients with hemophilia. Thirty-eight of them were
adults and 23 were pediatric patients younger than 18
years. The study was performed in accordance with
the principles of Helsinki Declaration and approved
by Ethics Committee. All hemophilia patients or their
parents (for the group of pediatric patients) signed
informed patient consent forms.
To analyze association between HLA class II al-
leles and natural clearance of HCV, the gene frequency
was compared in hemophilia patient group (n=44) and
the control group of healthy subjects (n=60, all men).
The data on HLA class II alleles of the control group
were obtained from the database of the Laboratory of
Immunology of the Riga Stradins University.
Laboratory methods. Blood samples were analyzed
to detect anti-HCV, HCV RNA, and HCV genotypes.
Commercial enzyme-linked immunosorbent assay
(ELISA) kits were used to detect antibodies to HCV
(AxSYM system HCV version 3.0, Abbott, USA;
ORTHO HCV version 3.0, Ortho-Clinical Diagnostics
Ltd., USA; INNOTEST HCV Ab IV, Innogenetic,
Belgium; MONOLISA anti-HCV PLUS version 2,
BIO-RAD, France). Serum HCV RNA was qualitative-
ly determined by a commercially available reverse
transcription polymerase chain reaction (PCR) method
(AMPLICOR Hepatitis C Virus Test, version 2.0,
Roche Molecular Systems, Inc., NJ, USA). HCV ge-
notype was determined using a method of reverse
hybridization LiPA (The VERSANT HCV Genotype
Amplification Kit (LiPA), Bayer Corporation, Ger-
many). HLA class II alleles were determined by PCR
method. DNA isolation was performed as follows:
genomic DNA was extracted from proteinase K-treat-
ed peripheral blood leukocytes with the routine meth-
od of salt off. The DNA was stored in TE buffer (10
mL Tris-HCl, pH 7.5, and 2 mL 0.5 M Na2 EDTA/L
d-H2O). We used DNA obtained stamps for genoty-
ping or storing in –20°C. DNA concentration was
determined by fluorescent method with DNA fluori-
meter and was 100–200 µg/mL in the middle. Dry
DNA and resuspend in TE buffer (25). HLA-DR and
-DQ Genotyping by PCR: low-resolution HLA-DR
typing for DRB1*01 through 18 as well as for
DQB1*0201-202, *0301-305, *0401-402, *0501-504,
*0601-608 was performed by PCR method with
amplification with sequence-specific primers (PCR-
SSP). The reaction mixture (15 µL) contained: 1 µL
DNA, 1.5 µL PCR buffer [50 mM KCl, 1.5 mM
MgCl2, 10 mM Tris-Cl, (pH 8.3)], 0.6 µL dNTPs (25
mmol/L), 1.0 µL specific primers (0.2 mol/L), and
0.5 U of the Taq DNA polymerase (Promega). In
addition, the internal positive control primer pair, C3
and C5, was included in all reaction mixtures at a
concentration of 5-fold lower than the allele- and
group-specific primers. The reaction mixture was sub-
jected to 35 amplification cycles (Program the Ther-
mo-Cycler DNA-technology, Russia), each consisting
of denaturation at 94°C (60 s), followed by one cycle,
annealing at 94°C (20 s), 67°C (2 s) followed by seven
cycles and extension at 93°C (5s), 65°C (4s) with a
final extension step 28 cycles. PCR products were
visualized by agarose gel electrophoresis. After
addition of 2 M loading buffer, the PCR reaction
mixtures were loaded in agarose gels pre-stained with
ethidium bromide (0.5 µk/mL gel). Gels were run for
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15 min at 10 V/cm gel in 0.5 mM TBE buffer, then
examined under UV illumination, and documented
(25, 26).
Statistical analysis. The distribution of HLA-
DRB1*, HLA-DQA1*, and HLA-DQB1* alleles in
hemophilia patients and control group subjects was
compared using Pearson’s chi-square (χ2) test with
Mantel-Haenszel correction or Fisher’s exact probabil-
ity test when expected value was less than 5. P values
less than or equal to 0.05 were regarded as statistically
significant. Odds ratios (ORs) were used in place of
relative risk. SPSS statistical software version 14 and
Microsoft Excel 2003 were used.
Results
HCV infection in hemophilia patients. HCV infec-
tion is common among hemophilia patients in Latvia.
Antibodies to HCV were found in majority of hemo-
philia patients (Table 1). HCV infection is more
frequently found in adults (89% or 34 of 38) than in
pediatric patients (48% or 11 of 23). Twenty-three
children, born between 1987 and 2004, were included
in the study. All children who cleared virus sponta-
neously were born during the period from 1990 to
1994. From all hemophilia patients with positive anti-
bodies to HCV, persistent hepatitis C was determined
in 26 (58%) patients. In one patient, sustained viral
response was achieved by monotherapy with inter-
feron-alpha before this study. This patient was ex-
cluded from calculations when assessing the frequency
of natural clearance of HCV.
HCV genotype distribution. Hepatitis C virus geno-
types 1b, 3a, and 2 were found in 16 (61%), 8 (31%),
and 2 (8%) patients, respectively. Since there are no
precise data on distribution of HCV genotypes in Lat-
vian population, comparison with different patient
groups (27, 28) was made (Table 2).
Natural clearance of HCV. In 41% (18 of 44) of
hemophilia patients, HCV infection resolved sponta-
neously. Children cleared HCV more frequently than
adults (7 of 11 (63.63%) comparing to 11 of 33
(33.33%), respectively; OR=3.50; P<0.05). Adults ol-
der than 40 years cleared HCV more often as com-
pared to those younger than 40 years (5 of 10 (50%)
comparing to 6 of 24 (25%), respectively; OR=3.00;
P<0.23). Differences between frequencies of natural
clearance did not reach statistical significance due to
a small number of hemophilia patients.
HLA class II alleles in hemophilia patients in
Latvia. The frequency difference was found to be
statistically significant when comparing the distribu-
tion of HLA class II alleles in hemophilia patient group
(n=60) and control group (n=60): HLA-DRB1*05
(corresponding number of alleles – 32 (26.67%) and
17 (14.17%)), HLA-DRB1*07 (corresponding num-
ber of alleles – 16 (13.33%) and 2 (1.67%)) and HLA-
DQB1*0502-4 (corresponding number of alleles – 14
(11.67%) and 4 (3.33%)), Table 3.
Table 1. Prevalence of HCV infection in patients with hemophilia in Latvia
         Category Adults Children All patientsn (%) n (%) n (%)
Positive anti-HCV 34 (89) 11 (48) 45 (74)
Negative anti-HCV 4 (11) 12 (52) 16 (26)
Total 38 23 61
Anti-HCV – antibodies to hepatitis C virus.
Table 2. Distribution of HCV genotype in different patient groups
     HCV Hemophilia patients Hemophilia patients Chronic hepatitis Cin USA in Latvia patients in Lithuania  genotype n (%) (n=31) n (%) (n=26) n (%) (n=1097)
1a 10 (32) 0 0
1b 4 (13) 16 (61.5) 678 (61.8)
2 2 (6) 2 (7.7) 100 (9.1)
3 13 (43) 8 (30.8) 319 (29.1)
4a 1 (3) 0 0
Mixed 1 (3) 0 0
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There are reports about association of HLA class
II alleles with inhibitor formation to coagulation fac-
tor VIII (29). In our study, there was no statistically
significant difference between groups of alleles re-
lated to inhibiting antibody formation to coagulation
factor VIII: HLA-DQA1*0102, HLA-DQB1*0602-8,
and HLA-DRB1*01.
HLA class II alleles in hemophilia patients with
natural clearance of HCV. The frequency difference
was found to be statistically significant when compar-
ing the distribution of HLA alleles in the sample of
hemophilia patients who naturally cleared HCV (n=18)
and in the control group (n=60): HLA-DRB1*07
(corresponding frequency of allele – 4 (11.11%) and
9 (1.67%)), Table 4. There was no statistically signifi-
cant difference in frequency distribution of allele
DQB1*0301 between hemophilia patients and control
group.
HLA class II alleles in pediatric hemophilia pa-
tients with natural clearance of HCV. Because of the
very high number of children, who have cleared HCV
naturally, we undertook comparison of HLA II class
genes of these children (n=7) with the control group
of 60 healthy subjects. The frequency difference was
found to be statistically significant when comparing
HLA allele distribution in the sample of hemophilia
patients – children who naturally cleared HCV (n=7)
and in the control group (n=60): HLA-DRB1*03
(frequency of the allele correspondingly 21.43% and
5%) and DQB1*0401-2 (21.43% and 3.3%), Table 5.
In hemophiliacs – children with persistent hepatitis
C – HLA alleles DRB1*07 (25% and 1.67%; OR=
19.67; P<0.0003) and DQA1*0401 (12.50% and
1.67%; OR=8.43; NS) were found more frequently
when comparing with the control group.
Discussion
In comparison to the literature data, where approxi-
mately 20% of patients have been shown to clear HCV
infection naturally, in our report it reaches 64% in
pediatric group. In adult hemophilia patients in Latvia,
natural clearance of HCV virus shown in our study is
33%.
It is possible and has been also confirmed by other
Table 3. Frequencies of HLA alleles in hemophilia patients and controls
Number of alleles Number of alleles
  HLA allele in hemophilia patients in control group P value OR
n (%) (n=120) n (%) (n=120)
DRB1*05 32 (26.67) 17 (14.17) 0.02 2.20
DRB1*07 16 (13.33) 2 (1.67) 0.0006 9.08
DQB1*0502-4 14 (11.67) 4 (3.33) 0.0145 3.83
Only statistically significant results are displayed.
Table 4. Frequencies of HLA allele in hemophilia patients with natural clearance of HCV and controls
Number of alleles Number of alleles
  HLA allele in hemophilia patients in control group P value OR
n (%) (n=36) n (%) (n=120)
DRB1*07 4 (11.11) 9 (1.67) 0.026* 7.38
*Fisher exact two-sided test. Only statistically significant results are displayed.
Table 5. Frequencies of HLA alleles in pediatric hemophilia patients
with natural clearance of HCV and controls
Number of alleles Number of alleles
  HLA allele in hemophilia patients in control group P value OR
n (%) (n=14) n (%) (n=120)
DRB1*03 3 (21.43%) 6 (5.00%) 0.02 5.18
DQB1*0401-2 3 (21.43%) 4 (3.33%) 0.025* 7.91
*Fisher exact two-sided test. Only statistically significant results are displayed.
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studies that patient age at the time of infection is a
positive factor that influences clearance from HCV
infection. It seems that immune response of young
patients is more effective.
The findings in this small study are consistent with
HCV genotype 1b prevalence in general population
in Latvia although there are no large studies available.
It is impossible to determine which HCV genotypes
were involved in those cases where natural clearance
had occurred. Possibly those were genotypes 2 and
3a. Although genotype 3a is more frequently found
in hemophilia patients in the USA, comparing to
general population, it seems to be the same (approxi-
mately 30%) in both groups in the Baltic States.
There are many factors – external (HCV genotype,
route of infection) and internal (genetic) – that contrib-
ute to the outcome of HCV infection.
Multiple transfusions of infected blood product
also could boost host immune responses against HCV.
Hemophilia patients are likely to have been re-infected
several times with different HCV genotypes and HCV
quasispecies. The mechanism of strong antiviral re-
sponse in those hemophilic patients, who, despite mul-
tiple exposures to virus, cleared HCV successfully, is
not clearly investigated and understood.
The fact that among adult hemophilia patients older
than 40 years, HCV cleared more often comparing to
those younger than 40 years also leads to thoughts
that long-term multiple exposure to the virus could
contribute to more successful results in the fight be-
tween host and pathogen. Since differences between
the groups did not reach statistical significance, it
would be important to conduct studies in bigger coun-
tries, involving a greater number of hemophilia pa-
tients.
There were no statistically significant differences
observed between frequency distribution in hemoph-
ilia patients who cleared HCV naturally and control
groups of alleles, more frequently described in the litera-
ture in association with HCV clearance – DQB1*0301
and DRB1*1101. The allele DRB1*07 is described
in literature in association with persistent HCV infec-
tion (21). Indeed, in our study, DRB1*07 was also
quite often found in the hemophilia patients with
chronic hepatitis C. At the same time, there is an asso-
ciation observed between allele DRB1*07 and suc-
cessful response to interferon-alpha treatment (30).
Much more complex immune response mechanisms
are involved in clearance of HCV and, even if the
association is found between a single allele and
different outcomes of HCV infection, this fact should
be addressed with care.
It is unlikely that predicting the outcome of HCV
infection based on HLA class II gene frequency will
be clinically useful in the closest future. Extremely
high polymorphism of HLA class II genes is observed
in different populations and patient groups.
Incidence of HLA class II alleles, known to be
related to formation of inhibitors to coagulation factor
VIII, was even lower in hemophilia patients group
comparing to healthy subjects. There is possibly less
risk of developing inhibitor antibodies to factor VIII
used for treatment in hemophilia patients in Latvia.
Studies of the association between HLA complex
and different outcomes of HCV infection should be
performed in larger groups in the future, taking into
account the results from the smaller studies in different
patient groups and populations. Planning of these stud-
ies has to be performed with caution, since it is already
known based on studies in hemophilia patients with
HCV infection that genetic factors are complex and
play only a modest role in spontaneous clearance of
HCV and other outcomes of HCV infection.
Conclusions
Natural clearance of HCV infection is frequently
found in hemophilia patients in Latvia. Persons more
likely to clear virus naturally are children and those
adult hemophilia patients with a long history of treat-
ment with blood products. There is an association be-
tween natural clearance of HCV infection and HLA
allele DRB1*07 in hemophilia patients in Latvia. In
children, there is an association between natural clear-
ance of HCV infection and HLA alleles DRB1*03
and DQB1*0401-2. These alleles could contribute to
successful clearance of HCV infection.
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organizme.
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